Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor

Antzeko izenburuak

• A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib
  nork: Yu, Helena A., et al.
  Argitaratua: (2016)
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  nork: Pao, William, et al.
  Argitaratua: (2005)
• EGFR exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib
  nork: Naidoo, J, et al.
  Argitaratua: (2015)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  nork: Oxnard, Geoffrey R., et al.
  Argitaratua: (2011)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  nork: Chaft, Jamie E., et al.
  Argitaratua: (2011)